VAXCYTE INC (PCVX)
Health Care · biotechnology (vaccines) · NASDAQ
Vaxcyte is a clinical-stage vaccine company leveraging a novel cell-free protein synthesis platform to develop next-generation, broad-spectrum pneumococcal conjugate vaccines.
What VAXCYTE INC does
Vaxcyte is a clinical-stage biotechnology company focused on developing high-fidelity vaccines to prevent bacterial diseases. Its proprietary XpressCF™ cell-free protein synthesis platform allows for the production of complex antigens designed to provide broader protection than conventional vaccine approaches. The company's lead product pipeline centers on broad-spectrum pneumococcal conjugate vaccine (PCV) candidates, such as VAX-31, for the prevention of invasive pneumococcal disease and pneumonia.
Themes: vaccine innovation, pneumococcal disease prevention, biotechnology platform / cell-free synthesis, infectious disease
Fundamentals
- Price$62.62 as of 2026-08-21 close
- Market cap$9.3B as of 2026-08-21
- 1-year return+96.2% 2025-08-21 close $31.91 → 2026-08-21 close $62.62
- P/En/a earnings data not available
- ROE-37.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.24 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How PCVX compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
PCVX is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
65.7 #40 of 1,704 scored · #16 of 240 in Health Care
Trend 80th: a strong uptrend, with buyers in control; volume and participation 74th: trading volume is about normal versus its 30-day average; weakest is setup 47th: over the past year its closes ranged, and it has retraced only a small part of its move over the past year — 2% of it.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How VAXCYTE INC looks technically
VAXCYTE INC (PCVX) is trading 18.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 179 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 3.7% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 18.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +18.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $56.12 | $56.12 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $53.02 | $53.02 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 52.47. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 179 trading days ago — a "golden cross", a bullish long-term signal | 179 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control | 33.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 62.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($53.61 to $63.98) — its "stochastic" reading is 87 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 86.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $65.00 | $65.00 |
|---|---|---|
| From the 52-week high | it is 3.7% below its 52-week high (its highest price of the past year) | -3.7% |
| Above the 52-week low | it is 109.6% above its 52-week low (its lowest price of the past year) | +109.6% |
| Below the 52-week high | it is 3.7% below its highest point of the past year | 3.7% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $121.06 (set on 2024-09-19) | $121.06 |
| Given back of the 52-week move | over the past year its closes ranged ($30.25 to $63.30), and it has given back only a small part of its rise from last year’s low — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $41.82 to $42.88. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 2.1% |
| From the all-time high | it is 48.3% below its all-time high | -48.3% |
| Nearest price level | it is trading 6.2% above a support level at $58.77 — a price it turned at twice since 2026-02-03, most recently on 2026-07-22. Since 2024-08-21 it has 11 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -6.2% |
| All-time low | its lowest closing price on record is $15.51 (set on 2021-05-11) | $15.51 |
| Above the all-time low | it is 303.7% above its all-time low | +303.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 62nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.42 between its high and its low — about 3.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.42 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $51.92 and $63.63 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $51.92 – $57.78 – $63.63 |
| Typical daily range (% of price) | its price moves about 3.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.9% |
| Stretch from the 200-day average | it is trading 4.0 daily ranges above its 200-day average price (18.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.22× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.4% |
|---|---|---|
| Open gap | it gapped 3.0% above the previous close 2 sessions ago and has not traded back through the level it left behind at 59.79 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.0% |
| Gap filled | a 2.6% gap up opened on 2026-06-18 has been "filled" 44 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 44 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 5.6 percentage points (the stock gained 7.9% while the market gained 2.3%) | +5.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 29.0 percentage points (the stock gained 32.1% while the market gained 3.1%) | +29.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 4.0 percentage points (the stock gained 7.0% while the market gained 11.1%) | -4.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 75.8 percentage points (the stock gained 96.2% while the market gained 20.5%) | +75.8% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.9% of the share price. | +11.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $54.93 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +14.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $59.71 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +4.9% |
Price levels it has turned at before
PCVX last closed at $62.62 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $58.77 | Support | 6.2% below the last close | turned there twice · 2026-02-03 to 2026-07-22 |
| $52.60 | Support | 16.0% below the last close | turned there twice · 2026-03-30 to 2026-07-29 |
| $51.41 | Support | 17.9% below the last close | turned there twice · 2026-02-11 to 2026-05-29 |
| $76.96 | Resistance | 22.9% above the last close | turned there four times · 2024-08-28 to 2025-03-21 |
| $94.27 | Resistance | 50.5% above the last close | turned there twice · 2024-12-02 to 2025-01-28 |
| $119.06 | Resistance | 90.1% above the last close | turned there twice · 2024-09-10 to 2024-10-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $52.47.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $68.94 and $79.12 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $52.47.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · At the top of its 14-day range (stochastic above 80) · Trading above the Ichimoku cloud · Most technical signals bullish | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.27 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$109.00 range $67.00 – $163.00; median $110.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PCVX
- Consensus EPS estimate-$2.14 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on unproven cell-free protein synthesis technology for commercial-scale manufacturing.","Clinical development risks inherent in achieving regulatory approval for complex vaccine candidates.","Intense competition from established global pharmaceutical companies with existing standard-of-care vaccines."]
What changed in the latest 10-Q
AI-assisted comparison of PCVX's 10-Q filed 2026-05-06 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to audited consolidated financial statements filed February 24, 2026 (vs. February 25, 2025 in older filing)
- Added specification that VAX-31 coverage includes 'approximately 88% of pneumococcal pneumonia circulating in adults in the United States aged 50 and older' (new quantification)
- Added language about 'incremental 19-31% of coverage for pneumococcal pneumonia over current standard-of-care adult PCVs' (new metric)
- Added details on dosing specifics: 'In the Low, Middle and High Doses, all serotypes were dosed at 1.1mcg, 2.2mcg and 3.3mcg, respectively' (capitalization of 'Doses' changed)
- Added announcement that FDA expanded BTD in August 2025 to include prevention of pneumonia caused by Streptococcus pneumoniae
- Added detail that in December 2025, following FDA End-of-Phase 2 meeting, first participants were dosed in OPUS-1 Phase 3 trial
- Added announcement that OPUS-1 enrollment was completed in March 2026
- Added expectation to announce OPUS-1 topline data in fourth quarter of 2026
- Added initiation of OPUS-2 Phase 3 trial in January 2026 (concomitant administration with high-dose seasonal influenza vaccine)
- Added initiation of OPUS-3 Phase 3 trial in February 2026 (for previously vaccinated adults)
- Added completion of OPUS-2 enrollment in March 2026 and OPUS-3 enrollment in May 2026
- Added expectation to report OPUS-2 and OPUS-3 data in first half of 2027
- Added mention of planning for manufacturing consistency study (lot-to-lot study)
- Removed:
- Removed reference to 'modern synthetic techniques, including advanced chemistry and' from XpressCF platform description
- Removed reference to platform being 'exclusively licensed from Sutro Biopharma, Inc. ("Sutro Biopharma")'
- Removed language about system intended to 'accelerate our ability to efficiently create and deliver'
- Removed language that serotypes are 'responsible for a significant portion of IPD' (changed to 'increasing portions')
- Removed language about maintaining coverage 'through continued vaccination practice' (simplified to 'continued vaccination')
- Removed description of VAX-31 coverage limited to 'approximately 95% of IPD' without pneumonia metric
- Removed language about 'incremental 14-34% of coverage over current standard-of-care adult PCVs' (replaced with more specific metrics)
- Removed paragraph describing planned Phase 3 initiation in December 2025, topline data announcement in 2026, and remaining Phase 3 initiation in 2026
- Removed language about 'the totality of VAX-31 data in adults' in dose selection rationale
- Removed parenthetical dose specification '(all serotypes dosed at 3.3mcg or 4.4mcg)'
- Removed planned BLA submission language
- Removed section on VAX-24 pediatric indication including March 2025 interim data announcement and November 2025 final data results
- Reworded:
- Changed 'designed to protect' to 'engineering high-fidelity vaccines to protect' in company description
- Changed 'developing broad-spectrum conjugate and novel protein vaccines' to 'engineering high-fidelity vaccines' (simplified description)
- Changed 'through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform' to 'through the XpressCF™ cell-free protein synthesis platform' (removed reference to other techniques)
- Changed 'Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits' to 'Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits'
- Changed 'responsible for a significant portion of IPD in circulation' to 'responsible for increasing portions of IPD in circulation'
- Changed dose capitalization from 'Low, Middle and High doses' to 'Low, Middle and High Doses' (and similar instances)
- Restructured VAX-31 adult indication details to separate coverage metrics for IPD and pneumonia with specific percentages
- Notes:
- Older filing appears truncated at the VAX-24 pediatric section; comparison limited to text provided
- Changes reflect progression of clinical development timeline between November 2025 and May 2026 filings
Risk Factors
- Added:
- Newer filing (2026-05-06) adds: 'Our net losses were $766.6 million and $463.9 million for the years ended December 31, 2025 and 2024, respectively, and $320.6 million and $140.7 million for the three months ended March 31, 2026 and 2025, respectively.'
- Newer filing (2026-05-06) adds: 'As of March 31, 2026, we had an accumulated deficit of $2.5 billion.'
- Newer filing (2026-05-06) adds: 'As of March 31, 2026, we had cash, cash equivalents and investments of $2.7 billion.'
- Removed:
- Older filing (2025-11-04) removes: 'Our current vaccine candidate pipeline includes two clinical and three preclinical programs.'
- Older filing (2025-11-04) removes net loss figures: '$463.9 million and $402.3 million for the years ended December 31, 2024 and 2023, respectively, and $212.8 million and $103.1 million for the three months ended September 30, 2025 and 2024, respectively, and $520.1 million and $326.8 million for the nine months ended September 30, 2025 and 2024, respectively.'
- Older filing (2025-11-04) removes: 'As of September 30, 2025, we had an accumulated deficit of $1.9 billion.'
- Older filing (2025-11-04) removes: 'As of September 30, 2025, we had cash, cash equivalents and investments of $2.7 billion.'
- Reworded:
- Reference date changed from 'September 30, 2025' to 'March 31, 2026' throughout the section for current financial position disclosures
- Notes:
- The older filing text appears truncated at the end ('following the init'), so the full comparison of the bullet point list may not be complete
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 32 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 11 sells ($3M) — 4 selling insiders
- Last 90 days0 buys · 32 sells ($7M) — 4 selling insiders
- Last 180 days0 buys · 33 sells ($7M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-05. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PCVX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 6 matched disclosures for PCVX from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding PCVX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 32,170,433
- Reported value $1,869,423,877
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PCVX had 14,464,951 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PCVX had 9.72% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.82 days to cover at the same settlement.
- Reported short interest (shares) 14,464,951
- Short interest (% of shares outstanding) 9.72%
- Prior settlement (shares) 14,231,919
- Reported change 1.64%
- Days to cover (reported) 14.82
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Pfizer (PFE)
- Merck (MRK)
- GSK (GSK)
- Sanofi (SNY)
- Moderna (MRNA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PCVX vs…
Frequently asked questions
What does VAXCYTE INC (PCVX) do?
Vaxcyte is a clinical-stage biotechnology company focused on developing high-fidelity vaccines to prevent bacterial diseases. Its proprietary XpressCF™ cell-free protein synthesis platform allows for the production of complex antigens designed to provide broader protection than conventional vaccine approaches.
What sector is VAXCYTE INC (PCVX) in?
VAXCYTE INC (PCVX) is classified in the Health Care sector. Its industry is biotechnology (vaccines). It trades on NASDAQ.
Who are VAXCYTE INC's (PCVX) competitors?
Notable peers of VAXCYTE INC (PCVX) include Pfizer, Merck, GSK, Sanofi and Moderna. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in PCVX?
Yes — we hold 6 matched STOCK Act disclosures for PCVX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is VAXCYTE INC (PCVX) overbought or oversold right now?
VAXCYTE INC (PCVX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PCVX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.